In a constantly changing landscape, Johnson & Johnson stands out for its recent strategies ofacquisition in the field of medical technologies. These bold moves aim to strengthen its medical device unit, while responding to a growing demand for innovative solutions, particularly in the sector cardiovascular. Thanks to an investment exceeding 30 billion dollars, J&J has integrated key businesses that propel its growth, balancing challenges faced in other industries.
Johnson & Johnson, healthcare giant, recently consolidated its medical devices unit with several strategic acquisitions. Over the past year, the company has invested more than 30 billion dollars to acquire companies such asAbiomed And Shockwave Medical. These steps have made it possible to significantly increase the sales in the cardiovascular sector, reaching nearly 2 billion dollars in the third quarter, representing growth of 26% compared to the previous year. As a result, despite challenges in other sectors such asorthopedics and the surgery, J&J’s cardiovascular group continues to support its entire business.
J&J’s strategic acquisitions
Recent acquisitions of Johnson & Johnson (J&J) in the sector of medical technologies were marked by a series of significant financial movements, exceeding $30 billion. This strategy aims to strengthen its unit of medical devices, notably thanks to the integration of companies like Shockwave Medical And Abiomed. These acquisitions allowed J&J to diversify and improve its market position, bringing with them cutting-edge technologies and valuable synergies.
The impact on the cardiovascular sector
J&J’s cardiovascular segment experienced a growth impressive, recording a year-over-year increase of 26.2%. Refocusing on this area has allowed the company to alleviate the difficulties encountered in other sectors, such as orthopedics. Thanks to this positive dynamic, sales exceeded $1.97 billion in the third quarter of 2024, a sign that strategic choices are taking shape. Investments in specialized companies such as Shockwave ensure continuity of innovations.
Market challenges and financial results
Despite the success of its acquisitions, J&J faces challenges, particularly in Asia, where problems such as the fight against corruption and value-based sourcing program impact sales. Growth forecasts for the unit medical technology were adjusted to 5% for 2024, below initial expectations of 6%. This readjustment illustrates the persistent tensions on the market and requires particular attention to maintain this path of growth.